Co-Diagnostics, Inc. (CODX)

Co-Diagnostics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	6.81	34.22	97.89	74.55	0.21
Revenue Growth (YoY)	-80.09%	-65.04%	31.30%	34579.90%	438.63%
Cost of Revenue	4.18	5.48	11.57	16.59	0.11
Gross Profit	2.63	28.74	86.31	57.96	0.1
Selling, General & Admin	21.14	21.61	24.95	12.94	4.56
Research & Development	22.96	17.44	14.96	3.19	1.37
Other Operating Expenses	1.23	16.67	0.34	0.14	0.07
Operating Expenses	45.33	55.72	40.25	16.27	6
Operating Income	-42.71	-26.98	46.06	41.69	-5.89
Interest Expense / Income	0	0	0	0	0.11
Other Expense / Income	-4.6	-8.13	0.43	-0.88	0.2
Pretax Income	-38.11	-18.85	45.64	42.57	-6.2
Income Tax	-2.78	-4.61	8.98	0.09	0
Net Income	-35.33	-14.24	36.66	42.48	-6.2
Net Income Growth	-	-	-13.70%	-	-
Shares Outstanding (Basic)	29	31	29	27	17
Shares Outstanding (Diluted)	29	31	30	28	17
Shares Change	-6.77%	5.27%	6.80%	67.10%	34.22%
EPS (Basic)	-1.20	-0.45	1.27	1.59	-0.37
EPS (Diluted)	-1.20	-0.45	1.23	1.52	-0.37
EPS Growth	-	-	-19.08%	-	-
Free Cash Flow	-23.45	5.14	40.41	27.39	-5.64
Free Cash Flow Per Share	-0.80	0.16	1.40	1.02	-0.34
Gross Margin	38.57%	83.98%	88.18%	77.75%	47.70%
Operating Margin	-626.92%	-78.85%	47.06%	55.93%	-2741.61%
Profit Margin	-518.68%	-41.61%	37.45%	56.98%	-2882.00%
Free Cash Flow Margin	-344.20%	15.02%	41.28%	36.74%	-2622.80%
Effective Tax Rate	-	-	19.67%	0.21%	-
EBITDA	-36.83	-17.53	45.97	42.71	-6.02
EBITDA Margin	-540.69%	-51.24%	46.96%	57.29%	-2801.84%
Depreciation & Amortization	1.28	1.31	0.34	0.14	0.07
EBIT	-38.11	-18.85	45.64	42.57	-6.09
EBIT Margin	-559.46%	-55.08%	46.62%	57.10%	-2832.49%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).